MediBeacon Receives $10 Million in Amended Agreements with Huadong Medicine to Accelerate Development of Transdermal GFR Measurement System
- Wednesday, November 16, 2022, 7:10
- PR Newswire
- Add a comment
MediBeacon approaching completion of Phase 3 study focused on kidney disease; Has submitted three of five required PMA modules needed for FDA approval ST. LOUIS, Nov. 16, 2022 /PRNewswire/ — MediBeacon Inc., a portfolio company within the Pansend Life Sciences segment of INNOVATE Corp….
About the Author
admin has written 21721 stories on this site.